Use of miRNAs in Growth Hormone Deficiency (GHD)

Summary

This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.

Eligibility

Inclusion Criteria for aim 1:

* Children with short stature and suspicion of GHD
* Subjects with organic GH deficiency

Exclusion criteria for aim 1:

-Subjects with underlying genetic conditions and chronic diseases

Inclusion Criteria for aim 2-3-5:

* patients having confirmed GHD enrolled for aim 1
* patients with growth failure and born SGA (\>4 yr of age)
* patients with Noonan and Turner syndrome and growth failure
* patients with short stature homeobox-containing gene deficiency (SHOXD) and growth failure

Inclusion Criteria for aim 4:

\- Isolated idiopathic prepubertal naive GHD subjects on long-acting versus daily GH therapy

Conditions2

Browse More Trials